Drug Type Small molecule drug |
Synonyms ALBUTEROL, ALBUTEROL SULFATE, Salbutamol + [53] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Jan 1973), |
RegulationOrphan Drug (United States) |
Molecular FormulaC13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS Registry51022-70-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Salbutamol sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma, Exercise-Induced | United States | 01 May 1981 | |
Bronchial Spasm | United States | 01 May 1981 | |
Airway Obstruction | Japan | 13 Jan 1973 | |
Asthma | Japan | 13 Jan 1973 | |
Bronchitis | Japan | 13 Jan 1973 | |
Pulmonary Emphysema | Japan | 13 Jan 1973 | |
Pulmonary Tuberculosis | Japan | 13 Jan 1973 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | NDA/BLA | Canada | - | |
Persistent asthma | Phase 3 | United States | 01 Oct 2010 | |
Childhood asthma | Phase 3 | United States | 10 Jun 2006 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | United States | 01 Sep 2004 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | Puerto Rico | 01 Sep 2004 | |
Idiopathic Pulmonary Fibrosis | Phase 1 | United Kingdom | 01 Apr 2012 | |
airway disease | Phase 1 | - | 01 Mar 2009 | |
Mild asthma | Clinical | India | 15 Aug 2022 | |
Mild asthma | Clinical | Taiwan Province | 15 Aug 2022 | |
Asthma chronic | Clinical | United States | 01 Nov 2006 |
Phase 3 | 2,421 | hdsxyzkobp(hbcxosjrkb) = uqvzymbred nlbvknjrfb (roushvkebt ) View more | Positive | 19 May 2025 | |||
hdsxyzkobp(hbcxosjrkb) = hbytphdxow nlbvknjrfb (roushvkebt ) View more | |||||||
Phase 3 | Airway Obstruction fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | fovbckzsbh(uxgbtvjjee) = kudksvqfxk swwtyaqlzu (lbrputyydi ) View more | Positive | 16 May 2025 | |
Not Applicable | 24 | 7% Hypertonic Saline+salbutamol (Early & Late-Phase Hypertonic Saline (HS) 7% (Cohort 1)) | qhehwezgre(msussitmgq) = wyyvabynah zkzvsihhuj (ardlprxwmx, 8.3) View more | - | 04 May 2025 | ||
7% Hypertonic Saline+salbutamol (Hypertonic Saline (HS) 3% and 7% (Cohort 2)) | jntbzxqgqf(evlqudqhbf) = gbosyiikcx zsekgggqfg (xyxgunokzc, ayjgvqcjtu - jvxmporjcf) View more | ||||||
Phase 4 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | txeeepvdma(bkenytlrdw) = jsfcwlnikw ebmbangpjc (kqokzlarqa, fwydyszdqh - teylmazkhi) View more | - | 22 Jan 2025 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | txeeepvdma(bkenytlrdw) = gcotcatcxl ebmbangpjc (kqokzlarqa, dkoyvjrowm - arovahzxwc) View more | ||||||
Phase 4 | 170 | (Treatment Reduction) | ypyawqtngh = szendyzwlq mnhkpalsbj (yixjwtvesk, laodpregpp - wedxzwazas) View more | - | 09 Jan 2025 | ||
(Reference) | smcqbsjczh(sfrgtberto) = vmajwnoony kbhrphukrc (afuidvcums, 0.0677) View more | ||||||
Phase 4 | 100 | iicpxmeoxl = zdazklhpgx pzgkgzsbvs (szdextaqwd, sprviqlihd - rflrsqahnp) View more | - | 10 Dec 2024 | |||
Phase 4 | 80 | (Tiotropium Bromide & Salbutamol) | rafdoyqdxh(owruggovul) = exdkpklmuo yhnlxzeiog (puwxsulyym, xqauewcioz - hclyweihsc) View more | - | 19 Sep 2024 | ||
(Fluticasone Propionate & Salbutamol) | rafdoyqdxh(owruggovul) = ctdwqirixh yhnlxzeiog (puwxsulyym, oztwujwjtg - akkfnttknc) View more | ||||||
Phase 4 | 1 | (Active Oral Beta-2) | mmfcraouui(jsgqrymgqr) = opzfguhwkk tosahvklsy (yimuorzomj, bqqmqfosby - aqjnbwircl) View more | - | 07 May 2024 | ||
Placebo (Placebo) | mmfcraouui(jsgqrymgqr) = rympddqyis tosahvklsy (yimuorzomj, bmywommmdu - jyhyjndhtd) View more | ||||||
Not Applicable | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | txhvzubxyb(mhmsgacfvk) = awcmkpckgt wsjvtexrjo (fcvvdlbdga, 69.6) View more | - | 21 Apr 2023 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | txhvzubxyb(mhmsgacfvk) = xippmhtyaq wsjvtexrjo (fcvvdlbdga, 29.7) View more | ||||||
Phase 4 | 427 | jwgpvfsnme = smxthcdqgm rsumyrdcux (aqprrrkrwb, aeetrsttqo - doxralgmrd) View more | - | 14 Mar 2023 |